Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study.

Abstract

FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV). To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris. A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted. Coprimary end points were the absolute change in inflammatory lesion count from baseline and the rate of treatment success (Investigator's Global Assessment score of 0 or 1 with a ≥2-grade improvement). There were 1488 participants in the intent-to-treat population. The FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline (P < .0001) and a greater rate of treatment success based on Investigator's Global Assessment (P < .0001) versus the foam vehicle group at week 12. FMX101 4% was generally safe and well tolerated. The efficacy and safety of FMX101 4% were not characterized in participants with mild AV. FMX101 4% topical minocycline foam was effective and safe for the treatment of moderate to severe AV.